X-Therma Inc., a Richmond, Calif.-based biotechnology firm growing expertise for regenerative medication and organ preservation, closed a $13M Sequence A funding spherical.
The spherical was led by Lorea AG, an entrepreneur-operated funding agency, with participation from Zen11 Holdings, Graphene Ventures, VU Enterprise Companions, 2b AHEAD Ventures, Methuselah Basis, Catalytic Impression Basis, together with angel traders.
The corporate intends to make use of the funds to scale commercialization of XT-Thrive®, to broaden its multi-disciplinary group, filling positions remotely (each nationally and internationally) in its San Francisco Bay Space headquarters and Austria subsidiary,
Led by Dr. Xiaoxi Wei, CEO & Co-Founder, and Dr. Mark Kline, CTO & Co-founder, X-Therma has developed chilly chain expertise through a convergent biopreservation platform, to advance Regenerative Medication and make obtainable protected and on-demand organs, engineered tissues, cell & gene therapies, vaccines, and past to sufferers in want.
X-Therma’s flagship product XT-Thrive®, a DMSO-, Serum-, Protein-free and chemically outlined cryopreservation answer straight plugs into the present CMC workflow, resolves bottlenecks within the cell manufacturing course of, and permits “off-the-shelf” residing medicines.
The corporate is headquartered in Richmond, a part of the San Francisco Bay Space, with analysis facilities in Richmond and Berkeley, and now has expanded to Europe in Austria.